宫颈癌规范治疗临床进展

doi:10.3760/cma.j.issn.1673-422X.2014.12.018

摘要/Abstract

摘要： 近年来随着治疗日趋规范，宫颈癌治疗疗效总体逐步提高，但对于局部晚期和复发、转移宫颈癌的治疗还有待进一步完善。早期宫颈癌根治性手术和根治性放疗疗效相当，中晚期宫颈癌同期放化疗是标准治疗，复发和转移宫颈癌使用抗血管生成治疗联合化疗能改善生存提高疗效，是否需要新辅助治疗有待进一步研究。

关键词: 宫颈肿瘤, 妇科外科手术, 放射疗法, 药物疗法, 分子靶向治疗

Abstract: In recent years, the efficacy of cervical cancer treatment has been increasing gradually. It has got a basic consensus of the standard treatment mode for most cervical cancer, but further effort should be done to improve the treatment response of locally advanced cervical cancer and recurrent or metastatic cervical cancer. The efect of redical surgery and radiotherpy is the same to early cervical cancer. Concurrent chemoradiotherapy is the standard treatment for patients with locally advanced cervical cancer. Chemotherapy combined with antiangiogenic targeted therapy can improve the survival of patients with recurrent or metastatic cervical cancer, while whether needing new adjuvant therapy or not, it asks for further investigation.

Key words: Uterine cervical neoplasms, Gynecologic surgical procedures, Radiotherapy ；Drug therapy, Molecular targeted therapy

白静. 宫颈癌规范治疗临床进展[J]. 国际肿瘤学杂志, 2014, 41(12): 937-940.

BAI Jing. Clinical progress of the standard treatment of cervical cancer[J]. Journal of International Oncology, 2014, 41(12): 937-940.

参考文献

［1］ Ueno S, Sudo T, Oka N, et al. Absence of human papillomavirus infection and activation of PI3KAKT pathway in cervical clear cell carcinoma［J］. Int J Gynecol Cancer, 2013, 23(6): 10841091. ［2］ Scatchard K, Forrest JL, Flubacher M, et al. Chemotherapy for metastatic and recurrent cervical cancer［J］. Cochrane Database Syst Rev, 2012, 10: CD006469. ［3］ Sandadi S, Tanner EJ, KhouryCollado F, et al. Radical surgery with individualized postoperative radiation for stage IB cervical cancer: oncologic outcomes and severe complications［J］. Int J Gynecol Cancer, 2013, 23(3): 553558. ［4］ Zheng M, Huang L, He L, et al. Evaluation of the effects of type Ⅱ radical hysterectomy in the treatment of 960 patients with stage ⅠBⅡB cervical carcinoma: a retrospective study［J］. J Surg Oncol, 2011, 103(5): 435441. ［5］ Kundargi RS, Guruprasad B, Rathod PS, et al. Risk stratabased therapy and outcome in stage ⅠbⅡa carcinoma cervix: singlecentre tenyear experience［J］. Ecancermedicalscience, 2013, 7: 341. ［6］ Jeon HW, Suh DH, Kim K, et al. Lymphadenectomy alone is a feasible option in managing incidentallydetected earlystage cervical cancer after simple hysterectomy without intermediaterisk factors: an application of the concept of less radical surgery［J］. Anticancer Res, 2013, 33(11): 51355141. ［7］ Chai Y, Wang T, Wang J, et al. Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage ⅡB cervical cancer［J］. BMC Cancer, 2014,14: 63. ［8］ Mabuchi S, Okazawa M, Isohashi F,et al. Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage ⅡB cervical cancer［J］. Gynecol Oncol, 2011, 123(2): 241247. ［9］ Rydzewska L,Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer［J］. Cochrane Database Syst Rev, 2012, 12: CD007406. ［10］ Wei LC, Wang N, Shi M, et al. Clinical outcome observation of preoperative concurrent chemoradiotherapy/radiotherapy alone in 174 Chinese patients with local advanced cervical carcinoma［J］. Onco Targets Ther, 2013, 6: 6774. ［11］ Lee DW, Lee KH, Lee JW, et al. Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stageⅡB cervical cancer?［J］. Int J Gynecol Cancer, 2013, 23(7): 13031310. ［12］ Prueksaritanond N, Chaisarn P, Yanaranop M. The efficacy of neoadjuvant paclitaxelcarboplatin chemotherapy followed by radical hysterectomy compared to radical hysterectomy alone in bulky stage ⅠB2ⅡA cervical cancer［J］. J Med Assoc Thai, 2012, 95 Suppl 3: S5561. ［13］ Yin M, Zhao F, Lou G et al. The longterm efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advancedstage cervical cancer［J］. Int J Gynecol Cancer, 2011, 21(1): 9299. ［14］ Wen H, Wu X, Li Z, et al. A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage ⅠB2 to ⅡA cervical cancer［J］. Int J Gynecol Cancer, 2012, 22(2): 296302. ［15］ Rajasooriyar C, Van Dyk S, Bernshaw D, et al. Patterns of failure and treatmentrelated toxicity in advanced cervical cancer patients treated using extended field radiotherapy with curative intent［J］. Int J Radiat Oncol Biol Phys, 2011, 80(2): 422428. ［16］ Kidd EA, Siegel BA, Dehdashti F, et al. Clinical outcomes of definitive intensitymodulated radiation therapy with fluorodeoxyglucosepositron emission tomography simulation in patients with locally advanced cervical cancer［J］. Int J Radiat Oncol Biol Phys, 2010, 77(4): 10851091. ［17］ Simpson DR, Song WY, Moiseenko V, et al. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin［J］. Int J Radiat Oncol Biol Phys, 2012, 83(1): e8186. ［18］ Du XL, Tao J, Sheng XG, et al. Intensitymodulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy［J］. Gynecol Oncol, 2012, 125(1): 151157. ［19］ RenardOldrini S, Brunaud C, Huger S, et al. Dosimetric comparison between the intensity modulated radiotherapy with fixed field and Rapid Arc of cervix cancer［J］. Cancer Radiother, 2012, 16(3): 209214. ［20］ Tharavichitkul E, Chakrabandhu S, Wanwilairat S, et al. Intermediateterm results of imageguided brachytherapy and hightechnology external beam radiotherapy in cervical cancer: Chiang Mai University experience［J］. Gynecol Oncol, 2013, 130(1): 8185. ［21］ Mazeron R, Gilmore J, Dumas I, et al. Adaptive 3D imageguided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer［J］. Oncologist, 2013, 18(4): 415422. ［22］ Lee HJ, Kim YS, Shin SS, et al. Longterm outcomes of concomitant chemoradiotherapy incorporating highdoserate brachytherapy to treat locally advanced cervical cancer［J］. Tumori, 2012, 98(5): 615621. ［23］ Lim A, Sia S. Outcomes of chemoradiotherapy in cervical cancer—the Western Australian experience［J］. Int J Radiat Oncol Biol Phys, 2012, 82(4): 14311438. ［24］ Kato S, Ohno T, Thephamongkhol K, et al. Longterm followup results of a multiinstitutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia［J］. Int J Radiat Oncol Biol Phys, 2013, 87(1): 100105. ［25］ Rose PG, Sill MW, McMeekin DS, et al. A phase Ⅰstudy of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study［J］. Gynecol Oncol, 2012, 125(1):158162. ［26］ Chakraborty S, Patil N. Randomized clinical trial of weekly vs. triweekly cisplatinbased chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(4): 13201321. ［27］ Tummers P, Makar A, Vandecasteele K, et al. Completion surgery after intensitymodulated arc therapy in the treatment of locally advanced cervical cancer: feasibility, surgical outcome, and oncologic results［J］. Int J Gynecol Cancer, 2013, 23(5): 877883. ［28］ Legge F, Margariti PA, Lucidi A, et al. Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: evaluation of toxicity and outcome measures［J］. Acta Oncol, 2013, 52(1): 166173. ［29］ Tang J, Tang Y, Yang J, et al. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma［J］. Gynecol Oncol, 2012, 125(2): 297302. ［30］ Gao Y, Gao F, Liu Z, et al. Treatment results of incomplete chemoradiotherapy in locally advanced cervical cancer［J］. Onco Targets Ther, 2013, 6: 297302.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[4]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[5]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[8]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[9]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[10]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[11]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[12]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[13]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[14]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[15]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.